With 10 incubators built to exacting pharmaceutical standards, the new facility will have a total incubation capacity of more than 2.5 million eggs and is expected to be operational in 2019.
Sanofi Pasteur produces more than 1 billion doses of vaccine each year and previously expanded its Swiftwater vaccine production capabilities with NatureForm equipment in 2006. Successful project management, validation capabilities and the ability to meet the stringent demands of human vaccine production were key factors in the company’s decision to work with NatureForm Hatchery Technologies again for this new expansion.
SmartPro™ NF incubation allows for precise, zonal temperature control, which delivers more viable embryos and therefore a greater vaccine yield. All incubators will be integrated with Sanofi Pasteur’s internal management software. Security badge scanners for access, specialized cooling coils, custom inlet and exhaust with filtration are just some of the specialized features that will be incorporated to ensure the equipment can be validated in this Biosecurity Level 2+ vaccine production facility.
Steve Warren, President of NatureForm Hatchery Technologies, comments, “We are extremely proud of our participation in this very important project. In 2016, Sanofi Pasteur enabled the vaccination of 200 million people against influenza worldwide and, together with our partner Pas Reform, we are honoured to be entrusted with such a significant component of their global vaccine production program.”